Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Informed Consent

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    28,934 result(s) found for: Informed Consent. Displaying page 717 of 1,447.
    «« First « Previous 713  714  715  716  717  718  719  720  721  Next» Last»»
    EudraCT Number: 2009-011137-26 Sponsor Protocol Number: P06129 Start Date*: 2009-10-05
    Sponsor Name:Schering-Plough Research Institute, A Division of Schering Corporation
    Full Title: An open-label study assessing the addition of subcutaneous golimumab (GLM) to conventional disease-modifying antirheumatic drug (DMARD) therapy in biologic-naïve subjects with rheumatoid arthritis ...
    Medical condition: Active Rheumatoid Arthritis
    Disease: Version SOC Term Classification Code Term Level
    14.0 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) FI (Completed) NL (Completed) HU (Completed) AT (Completed) FR (Completed) IE (Completed) IT (Completed) CZ (Completed) BE (Completed) GR (Completed) DK (Completed) SK (Completed) PT (Completed) PL (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2011-000410-18 Sponsor Protocol Number: 061002 Start Date*: 2011-05-05
    Sponsor Name:Baxter Innovations GmbH
    Full Title: A PHASE 3b CLINICAL STUDY TO ASSESS WHETHER REGULAR ADMINISTRATION OF ADVATE IN THE ABSENCE OF IMMUNOLOGICAL DANGER SIGNALS REDUCES THE INCIDENCE RATE OF INHIBITORS IN PREVIOUSLY UNTREATED PATIENTS...
    Medical condition: Prevention of inhibitor formation, and immune tolerance induction in patients with severe and moderately severe hemophilia A by early and low-dose prophylactic ADVATE therapy
    Disease:
    Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Under 18 Gender: Male
    Trial protocol: AT (Prematurely Ended) DE (Completed) SK (Prematurely Ended) LT (Prematurely Ended) GB (Prematurely Ended) HU (Prematurely Ended) CZ (Prematurely Ended) SE (Prematurely Ended) BE (Prematurely Ended) BG (Completed) ES (Prematurely Ended) NL (Prematurely Ended) GR (Prematurely Ended) PL (Prematurely Ended) PT (Completed)
    Trial results: View results
    EudraCT Number: 2005-003862-40 Sponsor Protocol Number: BO17708 Start Date*: 2006-01-20
    Sponsor Name:F. Hoffmann-La Roche Limited
    Full Title: Estudio multicéntrico, randomizado, doble ciego, controlado con placebo, para evaluar la eficacia y seguridad de bevacizumab en combinación con docetaxel, en comparación con docetaxel más placebo, ...
    Medical condition: Cáncer de mama metastásico Metastatic breast cancer
    Disease: Version SOC Term Classification Code Term Level
    8 10055113 PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Completed) BE (Completed) AT (Completed) GB (Completed) SE (Completed) PT (Completed) DE (Completed) LT (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2008-000228-13 Sponsor Protocol Number: EFC10572 Start Date*: 2008-08-22
    Sponsor Name:sanofi-aventis recherche & développement
    Full Title: A Multinational, Multicenter, Randomized, Double-Blind Study Comparing the Efficacy and Safety of AVE5026 with enoxaparin for the Primary Prevention of Venous Thromboembolism in Acutely Ill Medical...
    Medical condition: The subjects who will partcipate to this clinical trial are acutely ill medical patients with restricted mobility.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10049909 Venous thromboembolism prophylaxis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) LV (Prematurely Ended) FR (Completed) CZ (Completed) NL (Completed) HU (Completed) ES (Completed) PT (Completed) EE (Completed) BE (Completed) LT (Prematurely Ended) IT (Prematurely Ended) PL (Completed) SI (Completed) DE (Prematurely Ended) GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-004817-33 Sponsor Protocol Number: EFC10295 Start Date*: 2008-02-19
    Sponsor Name:sanofi-aventis recherche&développement
    Full Title: A multicenter, randomized, double-blind, assessor-blind, non-inferiority study comparing the efficacy and safety of once-weekly subcutaneous biotinylated idraparinux (SSR126517E) with oral adjuste...
    Medical condition: The subjects who will participate to this clinical trial are not healthy volonteers. They have Permanent, persistent or paroxysmal non-valvular atrial fibrillation that is ECG-documented, with an i...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) GB (Prematurely Ended) NL (Completed) ES (Completed) FI (Completed) EE (Completed) GR (Prematurely Ended) DK (Prematurely Ended) AT (Prematurely Ended) CZ (Prematurely Ended) SK (Completed) PT (Completed) BG (Completed) IT (Prematurely Ended) LT (Completed)
    Trial results: View results
    EudraCT Number: 2009-013652-69 Sponsor Protocol Number: AI447-016 Start Date*: 2010-01-19
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Phase 2a/2b study of BMS-650032 in Combination With Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) in Treatment-Naive Subjects with Genotypes 1 and 4 Chronic Hepatitis C Infection.
    Medical condition: Chronic Hepatitis C Virus Infection (Genotypes 1 and 4) in Treatment-Naive Subjects
    Disease: Version SOC Term Classification Code Term Level
    9.1 10008912 Chronic hepatitis C LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) GB (Completed) DE (Completed) ES (Completed) IE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2009-010551-26 Sponsor Protocol Number: D0102C00003 Start Date*: 2009-08-10
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase I/II Multi-centre Study of AZD8931 in Combination with Weekly Paclitaxel to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy in Patients with Advanced Solid Tumours and in a S...
    Medical condition: Phase I part of the study: Solid tumours that are refractory to standard therapies Phase II part of the study: trastuzumab- or lapatinib-ineligible patients with locally advanced (not amenable to s...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10049280 Solid tumour LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed) CZ (Completed) HU (Completed) SE (Completed) FR (Completed) IT (Completed) BG (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2007-002693-66 Sponsor Protocol Number: 0822-018 Start Date*: 2007-11-13
    Sponsor Name:MERCK SHARP & DOHME CORP.
    Full Title: A Phase III Randomized, Placebo-Controlled Clinical Trial to Assess the Safety and Efficacy of MK-0822 to Reduce the Risk of Fracture in Osteoporotic Postmenopausal Women Treated With Vitamin D an...
    Medical condition: Postmenopausal Osteoporosis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10028395 - Musculoskeletal and connective tissue disorders 10031285 Osteoporosis postmenopausal PT
    Population Age: Elderly Gender: Female
    Trial protocol: LT (Completed) DK (Completed) CZ (Prematurely Ended) PL (Prematurely Ended) GB (Prematurely Ended) DE (Completed) FR (Prematurely Ended) BE (Prematurely Ended) LV (Completed) EE (Completed) IT (Completed) ES (Completed) BG (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-004136-30 Sponsor Protocol Number: 20130213 Start Date*: 2014-03-05
    Sponsor Name:KAI Pharmaceuticals, Inc. (a subsidiary of Amgen, Inc.)
    Full Title: A Multicenter Single-arm Extension Study to Describe the Long-term Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis
    Medical condition: Secondary hyperparathyroidism in subjects with chronic kidney disease
    Disease: Version SOC Term Classification Code Term Level
    18.0 10014698 - Endocrine disorders 10020708 Hyperparathyroidism secondary PT
    18.0 10014698 - Endocrine disorders 10020706 Hyperparathyroidism NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) IT (Completed) BE (Completed) AT (Completed) ES (Completed) PT (Completed) LT (Completed) PL (Completed) CZ (Completed) DK (Completed) LV (Completed) DE (Completed) GR (Completed) HU (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2009-015834-31 Sponsor Protocol Number: CLCZ696B2314 Start Date*: 2010-01-01
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A multicenter, randomized, double-blind, parallel group, active-controlled study to evaluate the efficacy and safety of LCZ696 compared to enalapril on morbidity and mortality in patients with chro...
    Medical condition: Chronic Heart Failure
    Disease: Version SOC Term Classification Code Term Level
    15.1 100000004849 10008502 CHF LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PT (Completed) IS (Completed) GB (Completed) ES (Prematurely Ended) DE (Completed) HU (Completed) NL (Prematurely Ended) SE (Completed) IT (Prematurely Ended) RO (Completed) SK (Completed) FI (Completed) FR (Completed) DK (Completed) BE (Completed) CZ (Completed) LT (Completed) EE (Completed) LV (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2013-000366-11 Sponsor Protocol Number: TP0503 Start Date*: 2013-06-28
    Sponsor Name:Tillotts Pharma AG
    Full Title: A Randomised Active-Controlled Double-Blind and Open Label Extension Study to Evaluate the Efficacy, Long-term Safety and Tolerability of TP05 3.2 g/day for the Treatment of Active Ulcerative Colit...
    Medical condition: Ulcerative colitis
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004856 10045365 Ulcerative colitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) IE (Completed) CZ (Completed) FI (Completed) GB (Completed) DK (Completed) BE (Completed) ES (Prematurely Ended) PL (Completed) HU (Completed) LT (Completed) LV (Completed) BG (Completed) SK (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2008-002155-24 Sponsor Protocol Number: H3E-EW-S124 Start Date*: 2008-08-06
    Sponsor Name:Eli Lilly and Company Limited, UK
    Full Title: A Phase 3, Double-Blind, Placebo-Controlled Study of Maintenance Pemetrexed plus Best Supportive Care versus Best Supportive Care Immediately Following Induction Treatment with Pemetrexed + Cisplat...
    Medical condition: Advanced Non-Squamous Non Small Cell Lung cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10025055 Lung cancer non-small cell stage IV LLT
    9.1 10025054 Lung cancer non-small cell stage IIIB LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) GB (Completed) PT (Completed) ES (Completed) DE (Completed) FR (Completed) FI (Completed) BE (Completed) IT (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2007-005134-36 Sponsor Protocol Number: 1184.14 Start Date*: 2008-01-28
    Sponsor Name:Boehringer Ingelheim bv
    Full Title: A 24-week (+ 24 week extension), randomized, placebo-controlled (only 1st 12-week period), double–blind, parallel-group, efficacy and safety comparison of Tiotropium/Salmeterol (7.5 µg/25 µg) Inhal...
    Medical condition: Moderate to severe COPD
    Disease: Version SOC Term Classification Code Term Level
    9.1 10010952 COPD LLT
    9.1 10010953 COPD exacerbation LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended) ES (Completed) FI (Completed) PT (Prematurely Ended) DE (Prematurely Ended) BE (Completed) DK (Completed) FR (Completed) SE (Prematurely Ended) IT (Prematurely Ended) LV (Prematurely Ended) GR (Completed) LT (Prematurely Ended) EE (Prematurely Ended) SK (Completed) AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-005217-24 Sponsor Protocol Number: GS-US-326-1100 Start Date*: 2015-11-19
    Sponsor Name:Gilead Sciences, Inc
    Full Title: A Combined Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Induction and Maintenance Study Evaluating the Safety and Efficacy of GS-5745 in Subjects with Moderately to Severely Active Ulce...
    Medical condition: Ulcerative Colitis
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004856 10045365 Ulcerative colitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Prematurely Ended) CZ (Prematurely Ended) SK (Prematurely Ended) BG (Prematurely Ended) GB (Completed) AT (Prematurely Ended) DE (Completed) BE (Completed) NL (Prematurely Ended) LV (Prematurely Ended) SE (Prematurely Ended) ES (Completed) IE (Prematurely Ended) IS (Prematurely Ended) HR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-000587-17 Sponsor Protocol Number: MA21573 Start Date*: 2008-06-18
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: Multi-National Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of Tocilizumab in Patients with Active Rheumatoid Arthritis on Background Non-biologic DMARDs who have an Inadequat...
    Medical condition: Rheumatoid arthritis.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10039073 Rheumatoid arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) AT (Completed) SE (Completed) ES (Completed) FI (Completed) IE (Completed) PT (Completed) CZ (Completed) DK (Completed) FR (Completed) BE (Completed) NL (Completed) HU (Completed) DE (Completed) GR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2008-005492-94 Sponsor Protocol Number: 28850 Start Date*: 2009-04-30
    Sponsor Name:MERCK SERONO SA
    Full Title: OPEN LABEL TRIAL TO DETERMINE THE LONG TERM SAFETY OF SAFINAMIDE IN PARKINSON`S DISEASE PATIENTS
    Medical condition: IDIOPATHIC PARKINSON`S DISEASE
    Disease: Version SOC Term Classification Code Term Level
    9.1 10061536 Parkinson's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) DE (Completed) BE (Completed) GB (Completed) AT (Completed) EE (Completed) ES (Completed) HU (Completed) NL (Completed) FR (Completed) SK (Prematurely Ended) CZ (Completed) FI (Completed) PT (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2006-006277-24 Sponsor Protocol Number: EFC6145 Start Date*: 2008-04-10
    Sponsor Name:sanofi-aventis recherche et développement
    Full Title: A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED PARALLEL GROUP STUDY OF THE EFFICACY AND SAFETY OF 4 ADMINISTRATIONS OF XRP0038/NV1FGF 4mg AT 2–WEEK INTERVALS ON AMPUTATION OR ANY DEATH IN CRITICAL LI...
    Medical condition: Critical Limb Ischemia with skin lesions
    Disease: Version SOC Term Classification Code Term Level
    14.0 10047065 - Vascular disorders 10058069 Critical limb ischemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) HU (Completed) GB (Completed) CZ (Completed) GR (Completed) ES (Completed) AT (Completed) FI (Completed) SE (Completed) FR (Completed) EE (Completed) IT (Completed) DK (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2008-005575-96 Sponsor Protocol Number: LPL100601 Start Date*: 2008-11-26
    Sponsor Name:GlaxoSmithKline Research & Development, Ltd
    Full Title: A Clinical Outcomes Study of Darapladib versus Placebo in Subjects with Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE)
    Medical condition: chronic Coronary Heart Disease (cCHD)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) ES (Completed) HU (Completed) SE (Completed) DE (Completed) GB (Completed) SK (Completed) FR (Completed) DK (Completed) EE (Completed) BE (Completed) CZ (Completed) PL (Completed) BG (Completed) IT (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2013-001384-23 Sponsor Protocol Number: REG1-CLIN310 Start Date*: 2013-10-30
    Sponsor Name:Regado Biosciences, Inc.
    Full Title: A RANDOMIZED, OPEN-LABEL, MULTI-CENTER, ACTIVE-CONTROLLED, PARALLEL GROUP STUDY TO DETERMINE THE EFFICACY AND SAFETY OF THE REG1 ANTICOAGULATION SYSTEM COMPARED TO BIVALIRUDIN IN PATIENTS UNDERGOIN...
    Medical condition: Coronary Artery Disease (CAD) in patients undergoing Percutaneous Coronary Intervention (PCI)
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004849 10011085 Ischaemic coronary artery disorders HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Prematurely Ended) EE (Prematurely Ended) DE (Prematurely Ended) NL (Completed) PT (Prematurely Ended) AT (Completed) GB (Completed) IT (Prematurely Ended) BE (Completed) SK (Prematurely Ended) ES (Prematurely Ended) DK (Prematurely Ended) PL (Prematurely Ended) CZ (Prematurely Ended) FR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-000443-24 Sponsor Protocol Number: TR02-110 Start Date*: 2011-06-29
    Sponsor Name:Insmed Incorporated
    Full Title: Long Term Safety and Tolerability Study of Open-Label Liposomal Amikacin for Inhalation (Arikace™) in Cystic Fibrosis Patients with Chronic Infection due to Pseudomonas aeruginosa
    Medical condition: Pseudomonas aeruginosa pulmonary infection / colonisation in patients with cystic fibrosis
    Disease: Version SOC Term Classification Code Term Level
    14.0 10010331 - Congenital, familial and genetic disorders 10011763 Cystic fibrosis lung PT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) GB (Completed) BE (Completed) IE (Completed) DE (Completed) FR (Completed) SE (Completed) GR (Completed) AT (Completed) NL (Completed) DK (Completed) BG (Completed) PL (Completed) ES (Completed) IT (Completed) SK (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 713  714  715  716  717  718  719  720  721  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed May 28 21:01:51 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA